DSpace width= university logo mark
Japanese | English 

KURA > D. 附属病院 > d10. 学術雑誌掲載論文 > 1. 査読済論文 >


ファイル 記述 サイズフォーマット
HO-PR-OKUMURA-H-369.pdf73.24 kBAdobe PDF
タイトル: Living-donor lobar lung transplantation for broncho-bronchiolitis obliterans after allogeneic hematopoietic stem cell transplantation: does bronchiolitis obliterans recur in transplanted lungs?
著者: Okumura, Hirokazu
Ohtake, Shigeki link image link image
Ontachi, Yasuo
Ozaki, Jun
Shimadoi, Shigeru
Waseda, Yuko link image link image
Kondo, Yukio link image link image
Yamazaki, Hirohito link image link image
Takami, Akiyoshi link image
Yasui, Masahide
Date, Hiroshi
Nakao, Shinji link image link image
奥村, 廣和
大竹, 茂樹
御舘, 靖雄
島樋, 茂
早稲田, 優子
近藤, 恭夫
山﨑, 宏人
高見, 昭良
安井, 正英
中尾, 眞二
発行日: 2007年11月
出版社(者): 日本血液学会
雑誌名: International journal of hematology
ISSN: 0925-5710
巻: 86
号: 4
開始ページ: 369
終了ページ: 373
抄録: We report a successful case of living-donor lobar lung transplantation (LDLLT) for therapy-resistant broncho-bronchiolitis obliterans (BBO) after allogeneic hematopoietic stem cell transplantation (HSCT). Bronchiolitis obliterans (BO) is one of the late-onset noninfectious pulmonary complications that occur after allogeneic HSCT and is usually resistant to immunosuppressive therapy. A 17-year-old girl with acute lymphoblastic leukemia (ALL) had undergone allogeneic bone marrow transplantation (BMT) from an HLA-matched sibling in 1997. Five years later, she relapsed with ALL and was treated with chemotherapy following stem cell rescue and donor lymphocyte infusion from the original BMT donor. Eight months later, BBO resistant to immunosuppressive therapies, including rituximab, developed in combination with chronic graft-versus-host disease (GVHD). In February 2004, the patient underwent LDLLT from 2 other family members who were mismatched at 3 HLA loci. The patient has been in good health for more than 30 months following LDLLT and shows no sign of BBO in the transplanted lungs, just as with other patients who have undergone lung transplantation for BO associated with chronic GVHD. LDLLT may therefore be considered a viable therapeutic option for the treatment of BO after allogeneic HSCT.
DOI: 10.1532/IJH97.07045
URI: http://hdl.handle.net/2297/9573
資料種別: Journal Article
版表示: author
出現コレクション:1. 査読済論文

このアイテムを引用あるいはリンクする場合は次の識別子を使用してください。 http://hdl.handle.net/2297/9573



Valid XHTML 1.0! DSpace Software Copyright © 2002-2010  Duraspace - ご意見をお寄せください